Compare BAND & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | PEPG |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 113.3M |
| IPO Year | 2017 | 2022 |
| Metric | BAND | PEPG |
|---|---|---|
| Price | $20.26 | $1.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $20.40 | $11.17 |
| AVG Volume (30 Days) | 359.0K | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $11.33 | $1.01 |
| 52 Week High | $19.59 | $7.80 |
| Indicator | BAND | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 20.94 |
| Support Level | $13.20 | $1.17 |
| Resistance Level | N/A | $5.46 |
| Average True Range (ATR) | 1.04 | 0.25 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 97.77 | 8.96 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.